Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

115.65 +0.48 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,310,666
Open 114.50
Bid (Size) 115.60 (100)
Ask (Size) 116.80 (100)
Prev. Close 115.17
Today's Range 114.50 - 116.78
52wk Range 75.40 - 125.14
Shares Outstanding 2,531,374,696
Dividend Yield 2.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top dow jones movers in Tuesday's session ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill

Performance

YTD
+8.6%
+8.6%
1 Month
+2.2%
+2.2%
3 Month
-4.7%
-4.7%
6 Month
+13.6%
+13.6%
1 Year
+51.7%
+51.7%

More News

Read More
News headline image
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Top dow jones movers in Monday's session ↗
Via Chartmill
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
Via ACCESS Newswire
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
News headline image
VYM vs. SCHD: Which U.S. Dividend ETF Is a Better Buy? ↗
Via The Motley Fool
Topics ETFs
News headline image
Merck to Participate in the Jefferies Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Tuesday. ↗
Via Chartmill
News headline image
Merck Announces Third-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
Exploring the top movers within the dow jones index during today's session. ↗
Via Chartmill
Eight Weeks and Counting: Wall Street Returns With a New Fed Chair, Cheaper Oil, and More Questions Than Answers ↗
Via Chartmill
Topics Economy
News headline image
The 1 AI Stock I'd Put in a Time Capsule and Open in 2036 ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
Via MarketBeat
News headline image
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities ↗
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
Discover the top S&P500 movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Cisplatin-Ineligible Resectable Muscle-Invasive Bladder Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Reasons to Watch MRK and 1 to Stay Cautious
Via StockStory
Topics Stocks Supply Chain
News headline image
Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer
From Merck & Co., Inc.
Via Business Wire
News headline image
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally ↗
Via The Motley Fool

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 115.65
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/02/26 07:00 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 292.75B
How many shares of Merck & Co are outstanding?
Merck & Co has 293B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.